接受减毒活流感疫苗与灭活流感疫苗的哮喘儿童哮喘急性发作比较
在2007年7月1日至2014年3月31日期间,对Kaiser Permanente北加州2至<18岁有哮喘史的成员接种流感疫苗后因哮喘急性发作就诊(住院或急诊)的风险进行分析,共387,633剂次免疫接种,85%为灭活疫苗、15%为减毒活疫苗。接种灭活疫苗后风险间隔(1-14天)较对照间隔(29-42天)的OR为0.97(95%CI:0.82-1.15),接种减毒活疫苗后OR为0.38(95%CI:0.17-0.90),双重差分分析显示减毒活疫苗较灭活疫苗的OR比为0.40(CI:0.17-0.95,P=0.04)。结论认为≥2岁哮喘儿童接种两种疫苗后均未增加哮喘急性发作风险,且减毒活疫苗较灭活疫苗风险降低。
要点
- 在≥2岁哮喘儿童中,接种灭活流感疫苗后哮喘急性发作风险未增加(OR 0.97,95%CI 0.82-1.15)。
- 接种减毒活流感疫苗后哮喘急性发作风险降低(OR 0.38,95%CI 0.17-0.90)。
- 减毒活疫苗较灭活疫苗的哮喘急性发作风险更低(OR比0.40,95%CI 0.17-0.95,P=0.04)。
核心结论
- 在≥2岁有哮喘史的儿童中,接种减毒活流感疫苗或灭活流感疫苗后均未发现哮喘急性发作风险增加,且减毒活疫苗较灭活疫苗风险降低。
研究设计与样本
- 在2007年7月1日至2014年3月31日期间,对Kaiser Permanente北加州2至<18岁有哮喘史的成员中发生的灭活流感疫苗和减毒活流感疫苗接种及后续住院或急诊就诊的哮喘急性发作进行识别。
- 共纳入387,633剂次免疫接种,其中85%为灭活疫苗、15%为减毒活疫苗。
主要发现
- 接种减毒活疫苗的儿童较接种灭活疫苗者更少具有「当前或近期持续性哮喘」(25% vs 47%),更多具有「远程哮喘史」(47% vs 25%)。
- 接种灭活疫苗的哮喘儿童中,住院或急诊哮喘急性发作的风险间隔(1-14天)较对照间隔(29-42天)的OR为0.97(95%CI:0.82-1.15)。
- 接种减毒活疫苗的哮喘儿童中,住院或急诊哮喘急性发作的风险间隔(1-14天)较对照间隔(29-42天)的OR为0.38(95%CI:0.17-0.90)。
- 双重差分分析中,接种减毒活疫苗后哮喘急性发作的 odds 低于灭活疫苗(OR比:0.40,CI:0.17-0.95,P=0.04)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate whether there is a difference in the risk of asthma exacerbations between children with pre-existing asthma who receive live attenuated influenza vaccine (LAIV) compared with inactivated influenza vaccine (IIV). MATERIAL AND METHODS: We identified IIV and LAIV immunizations occurring between July 1, 2007 and March 31, 2014 among Kaiser Permanente Northern California members aged 2 to <18years with a history of asthma, and subsequent asthma exacerbations seen in the inpatient or Emergency Department (ED) setting. We calculated the ratio of the odds (OR) of an exacerbation being in the risk interval (1-14days) versus the comparison interval (29-42days) following immunization, separately for LAIV and IIV, and then examined whether the OR differed between children receiving LAIV and those receiving IIV ("difference-in-differences"). RESULTS: Among 387,633 immunizations, 85% were IIV and 15% were LAIV. Children getting LAIV vs. IIV were less likely to have "current or recent, persistent" asthma (25% vs. 47%), and more likely to have "remote history" of asthma (47% vs. 25%). Among IIV-vaccinated asthmatic children, the OR of an inpatient/ED asthma exacerbation was 0.97 (95% CI: 0.82-1.15). Among LAIV-vaccinated asthmatic children the OR was 0.38 (95% CI: 0.17-0.90). In the difference-in-differences analysis, the odds of asthma exacerbation following LAIV were less than IIV (Ratio of ORs: 0.40, CI: 0.17-0.95, p value: 0.04). CONCLUSION: Among children ≥2years old with asthma, we found no increased risk of asthma exacerbation following LAIV or IIV, and a decreased risk following LAIV compared to IIV.
引用
- Ray GT, Lewis N, Goddard K, et al. Asthma exacerbations among asthmatic children receiving live attenuated versus inactivated influenza vaccines. Vaccine. 2017. PMID: 28404355. doi:10.1016/j.vaccine.2017.03.082
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。